1. Comparison of clinico-pathological features of 582 patients with TNBC.
| Variables | cTNBC (n=429)
[n (%)] |
sTNBC (n=153)
[n (%)] |
P | Apocrine carcinoma
(n=71) [n (%)] |
cTNBC vs.
apocrine carcinoma |
Metaplastic carcinomas
(n=31) [n (%)] |
cTNBC vs. metaplastic
carcinomas |
Medullary carcinoma (n=20)
[n (%)] |
cTNBC vs.
medullary carcinoma |
| TNBC, triple negative breast cancer; cTNBC, conventional type of triple negative breast cancer; sTNBC, special type of triple negative breast cancer; DCIS, ductal carcinoma in situ; TIL, tumor infiltrating lymphocyte; HER2, human epidermal growth factor receptor; AR, androgen receptor; *, median (range); **, categorical variables were analyzed by Chi-squared test or Fisher’s exact test and continuous data were analyzed using the Student’st test. | |||||||||
| Age (year) * | 53 (24−93) | 60 (25−88) | <0.001 | 65 (39−88) | <0.001 | 55 (27−86) | 0.539 | 52 (39−68) | 0.451 |
| DCIS | |||||||||
| Low | 10 (6.5) | 13 (17.3) | 0.002 | 7 (13.7) | 0.001 | 0 (0) | 0.809** | 0 (0) | 0.318** |
| Middle | 78 (50.3) | 45 (60.0) | 36 (70.6) | 3 (60.0) | 2 (28.6) | ||||
| High | 67 (43.2) | 17 (22.7) | 8 (15.7) | 2 (40.0) | 5 (71.4) | ||||
| TILs | |||||||||
| Little | 59 (28.8) | 10 (20.8) | 0.330 | 5 (27.8) | 0.062 | 4 (40.0) | 0.307** | 0 (0) | 0.033** |
| Middle | 35 (17.1) | 12 (25.0) | 7 (38.9) | 3 (30.0) | 1 (8.3) | ||||
| Large | 111 (54.1) | 26 (54.2) | 6 (33.3) | 3 (30.0) | 11 (91.7) | ||||
| HER2 | |||||||||
| 0 | 204 (47.8) | 62 (40.8) | 0.200 | 16 (22.9) | <0.001 | 22 (71.0) | 0.028** | 14 (70.0) | 0.128** |
| 1+ | 154 (36.1) | 57 (37.5) | 32 (45.7) | 8 (25.8) | 5 (25.0) | ||||
| 2+ | 69 (16.2) | 33 (21.7) | 22 (31.4) | 1 (3.2) | 1 (5.0) | ||||
| AR (%)* | 10 (0−90) | 40 (0−90) | <0.001 | 63(0−90) | <0.001 | 12 (0−90) | 0.673 | 19 (0−90) | 0.297 |
| Neoadjuvant therapy | 167 (38.9) | 23 (15.0) | <0.001 | 7 (10.0) | <0.001 | 8 (25.8) | 0.128 | 3 (15.0) | 0.032** |
| Tumor regression score | |||||||||
| G1 | 27 (16.3) | 5 (23.8) | 0.057 | 2 (40.0) | 0.422 | 2 (25.0) | 0.051** | 0 (0) | 0.684** |
| G2 | 18 (10.8) | 3 (14.3) | 0 (0) | 1 (12.5) | 1 (33.3) | ||||
| G3 | 49 (29.5) | 5 (23.8) | 2 (40.0) | 1 (12.5) | 1 (33.3) | ||||
| G4 | 24 (14.5) | 7 (33.3) | 1 (20.0) | 4 (50.0) | 0 (0) | ||||
| G5 | 48 (28.9) | 1 (4.8) | 0 (0) | 0 (0) | 1 (33.3) | ||||
| Tumor size (cm)* | 1.80 (0.15−14.00) | 2.37 (0.20−12.00) | 0.491 | 2.00 (0.33−5.80) | 0.157 | 3.25 (0.20−12.00) | 0.008 | 1.91 (0.70−3.30) | 0.107 |
| Grade | |||||||||
| 1 | 1 (0.2) | 22 (14.6) | <0.001 | 13 (18.3) | <0.001 | 0 (0) | 0.726 | 0 (0) | 0.593** |
| 2 | 80 (18.8) | 63 (41.7) | 44 (62.0) | 4 (13.3) | 2 (10.0) | ||||
| 3 | 344 (80.9) | 66 (43.7) | 14 (19.7) | 26 (86.7) | 18 (90.0) | ||||
| Score* | 8 (5−9) | 7 (3−9) | <0.001 | 6 (3−9) | <0.001 | 8 (7−9) | 0.118 | 8 (7−9) | 0.338 |
| Duct formation | |||||||||
| 1 | 0 (0) | 3 (2.0) | <0.001 | 3 (4.3) | <0.001 | 0 (0) | >0.999** | 0 (0) | >0.999** |
| 2 | 12 (2.9) | 18 (12.0) | 14 (20.0) | 0 (0) | 0 (0) | ||||
| 3 | 407 (97.1) | 129 (86.0) | 53 (75.7) | 30 (100.0) | 20 (100.0) | ||||
| Nuclear grade | |||||||||
| 1 | 1 (0.2) | 8 (5.3) | <0.001 | 2 (2.9) | <0.001 | 0 (0) | 0.123** | 0 (0) | 0.625** |
| 2 | 233 (55.6) | 96 (64.0) | 57 (81.4) | 11 (36.7) | 9 (45.0) | ||||
| 3 | 185 (44.2) | 46 (30.7) | 11 (15.7) | 19 (63.3) | 11 (55.0) | ||||
| Mitotic activity | |||||||||
| 1 | 29 (6.9) | 59 (39.3) | <0.001 | 38 (54.3) | <0.001 | 1 (3.3) | 0.623** | 1 (5.0) | 0.944** |
| 2 | 64 (15.3) | 35 (23.3) | 22 (31.4) | 6 (20.0) | 3 (15.0) | ||||
| 3 | 326 (77.8) | 56 (37.3) | 10 (14.3) | 23 (76.7) | 16 (80.0) | ||||
| Mitotic count* | 25 (0−100) | 13 (0−63) | <0.001 | 7 (0−39) | <0.001 | 22 (2−63) | 0.336 | 23 (5−38) | 0.588 |
| Ki67 (%)* | 68 (0−95) | 42 (2−95) | <0.001 | 28 (3−90) | <0.001 | 56 (15−90) | 0.004 | 72 (20−95) | 0.510 |
| TNM | |||||||||
| 1 | 105 (37.8) | 42 (34.7) | 0.020 | 25 (42.4) | 0.099 | 6 (23.1) | 0.353** | 9 (52.9) | 0.009** |
| 2 | 107 (38.5) | 47 (38.8) | 23 (39.0) | 11 (42.3) | 3 (17.6) | ||||
| 3 | 9 (3.2) | 13 (10.7) | 5 (8.5) | 2 (7.7) | 3 (17.6) | ||||
| 4 | 57 (20.5) | 19 (15.7) | 6 (10.2) | 7 (26.9) | 2 (11.8) | ||||
| Prognosis stage | |||||||||
| 1 | 0 (0) | 1 (0.8) | 0.318 | 0 (0) | 0.120 | 1 (3.8) | 0.003** | 0 (0) | 0.441** |
| 2 | 106 (38.3) | 48 (39.7) | 29 (49.2) | 5 (19.2) | 9 (52.9) | ||||
| 3 | 114 (41.2) | 53 (43.8) | 24 (40.7) | 13 (50.0) | 6 (35.3) | ||||
| 4 | 57 (20.6) | 19 (15.7) | 6 (10.2) | 7 (26.9) | 2 (11.8) | ||||
| T | |||||||||
| 1 | 158 (57.0) | 61 (50.4) | 0.647 | 36 (61.0) | 0.764 | 8 (30.8) | 0.010** | 11 (64.7) | 0.721** |
| 2 | 100 (36.1) | 50 (41.3) | 21 (35.6) | 12 (46.2) | 6 (35.3) | ||||
| 3 | 12 (4.3) | 7 (5.8) | 1 (1.7) | 4 (15.4) | 0 (0) | ||||
| 4 | 7 (2.5) | 3 (2.3) | 1 (1.7) | 2 (7.7) | 0 (0) | ||||
| N | |||||||||
| 0 | 176 (64.2) | 79 (65.3) | 0.429 | 36 (61.0) | 0.825 | 20 (76.9) | 0.489** | 12 (70.6) | 0.001** |
| 1 | 83 (30.3) | 31 (25.6) | 18 (30.5) | 6 (23.1) | 2 (11.8) | ||||
| 2 | 5 (1.8) | 5 (4.1) | 2 (3.4) | 0 (0) | 3 (17.6) | ||||
| 3 | 10 (3.6) | 6 (5.0) | 3 (5.1) | 0 (0) | 0 (0) | ||||
| M | |||||||||
| 0 | 279 (79.7) | 104 (77.6) | 0.431 | 55 (82.1) | 0.161 | 19 (65.4) | 0.626** | 17 (89.5) | 0.381** |
| 1 | 71 (20.3) | 30 (22.4) | 12 (17.9) | 9 (34.6) | 2 (10.5) | ||||